Propanc Biopharma Announces That PRP Suppresses TGF-β Pathway & Tumor Microenvironment in Pancreatic Cancer

MELBOURNE, Australia--(BUSINESS WIRE)--Propanc Biopharma, Inc. (OTC Pink: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company developing novel cancer treatments for patients suffering

Related Keywords

Spain ,Melbourne ,Victoria ,Australia ,Granada ,Andalucísp ,Toledo Cutillas Msc ,James Nathanielsz ,Julian Kenyon ,Company Mechanism Of Action ,Propanc Biopharma Inc ,University Of Ja ,Exchange Commission ,Propanc Biopharma ,Toledo Cutillas ,Professor Macarena Per ,Chief Scientific Officer ,Press Release , ,